Clinical Trials
15
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
- Conditions
- Fallopian Tube CancerPrimary Peritoneal CarcinomaClear Cell CarcinomaOvarian Cancer
- Interventions
- Drug: 6 cycles chemotherapyDrug: 3 cycles chemotherapy instead of 6 cycles chemotherapy
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2025-04-27
- Target Recruit Count
- 640
- Registration Number
- NCT05460000
- Locations
- 🇧🇪
Cliniques Universitaires St. Luc, Brussels, Belgium
🇧🇪Jessa ziekenhuis, Hasselt, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
- Conditions
- Low Grade Serous CarcinomaOvarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2025-05-23
- Target Recruit Count
- 33
- Registration Number
- NCT04575961
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
🇩🇪Kliniken Essen Mitte, Essen, Germany
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
- Conditions
- Clear Cell CarcinomaOvarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
- Interventions
- Drug: Placebos
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 42
- Registration Number
- NCT04227522
- Locations
- 🇩🇪
Universitätsklinikum Aachen, Aachen, Germany
🇩🇪ANregiomed Frauenklinik Ansbach, Ansbach, Germany
🇩🇪Helios Klinikum Berlin-Buch, Berlin, Germany
Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer
- Conditions
- Primary Invasive Breast CancerEstrogen Receptor Positive TumorHuman Epidermal Growth Factor Receptor 2 Negative Tumor
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 1191
- Registration Number
- NCT03503799
- Locations
- 🇩🇪
Frauenklinik der Technischen Universität München, München, Bayern, Germany
🇩🇪ANregiomed Ansbach, Ansbach, Germany
🇩🇪Charité - Universitätsmedizin Berlin, Berlin-Mitte, Germany
QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer
- Conditions
- Recurrent Ovarian CarcinomaQuality of LifeOvarian Cancer
- Interventions
- Drug: Trabectidin (Yondelis)
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2025-03-20
- Target Recruit Count
- 89
- Registration Number
- NCT03164980
- Locations
- 🇩🇪
Universitätsklinikum Aachen, Aachen, Germany
🇩🇪Sankt Gertrauden-Krankenhaus, Berlin, Germany
🇩🇪Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
- Prev
- 1
- 2
- 3
- Next